Clean ClAImsFirst Pass

R1 RCM vs Veradigm

Two End-to-End RCM vendors, side by side. Facts from public sources; judgments are ours.

At a glance

Derived from public facts · a rough scale, not a ranking

R1 RCMVeradigm
Pricing model

Percent of collections · roughly 4-7% of net collections

Enterprise contract (custom) · Varies by product line

Speed to go live

full outsourcing with staff transitions

Clearinghouse light; EHR and RCM heavier

Automation model

Tech-enabled service · embedded teams plus AI automation

Software platform · Software plus data network and services

Built for

Enterprise systems

Small practices, Mid-size groups, Enterprise systems, Payers

Security posture

HITRUST, SOC 2 Type II, PCI DSS, HIPAA

SOC 2 Type II, HIPAA

Company maturity

23 yrs (est. 2003)

40 yrs (est. 1986)

Financial backing

PE-owned (TowerBrook and CD&R)

Public (OTC: MDRX)

Named customers

4 named

None public

Published results

No public numbers

No public numbers

Documented integrations

4 listed

4 listed

Third-party validation

None found

None found

Bottom line

  • Pick R1 RCM if you are a hospital or health system ready to hand the entire revenue cycle to an outside operator, staff included.
  • Pick Veradigm if you want a proven clearinghouse and ambulatory RCM stack from one vendor and can tolerate its corporate and financial-reporting turbulence.

R1 RCM

The largest end-to-end RCM operator

Founded
2003
HQ
Murray, UT
Stage
PE-owned (TowerBrook and CD&R)
Raised
n/a

What it does

  • Full outsourced revenue cycle operations, front door to final payment
  • Patient access, scheduling, and registration services at scale
  • Coding, billing, denials management, and underpayment recovery
  • Cloudmed revenue intelligence mines charts for missed revenue
  • R37 lab building agentic AI for coding and denials
  • Modular offerings for physician groups and hospitals

Where it's strong

  • Unmatched scale and data: serves 94 of the top 100 health systems and processes 550 million patient encounters a year.
  • Can take over the entire revenue cycle including staff, which few vendors can credibly offer a large health system.
  • The exclusive Palantir partnership (R37) gives it a serious platform for agentic AI across coding, billing, and denials.

What buyers should weigh

  • Full outsourcing means deep operational dependence; unwinding an R1 contract is a multi-year project.
  • Built for large health systems; small and mid-size groups are not the core market and get less attention.
  • PE ownership after the $8.9B take-private adds margin pressure, and the company has weathered customer disputes and a 2024 cyberattack ripple from partners.

Named customers

Ascension · Intermountain Health · AMITA Health · Quorum Health

Integrations

EpicOracle Health (Cerner)MeditechWorks across major hospital EHRs
Full R1 RCM profile →

Veradigm

Ambulatory RCM, clearinghouse network, and healthcare data at scale

Founded
1986
HQ
Chicago, IL
Stage
Public (OTC: MDRX)
Raised
n/a

What it does

  • Payerpath clearinghouse serving 300,000+ providers
  • Outsourced RCM services (Koha Health acquisition)
  • Veradigm EHR and Practice Fusion for ambulatory care
  • AI Ambient Scribe for clinical documentation
  • Payer analytics and risk adjustment
  • Real-world data for life sciences research

Where it's strong

  • Payerpath is repeatedly ranked the top physician claims clearinghouse by Black Book.
  • One vendor covers EHR, clearinghouse, RCM services, and an ambient scribe for ambulatory groups.
  • Its provider network gives it data assets few RCM vendors can match.

What buyers should weigh

  • Accounting failures got the stock delisted from Nasdaq in 2024; it still trades OTC while restating financials.
  • Strategic uncertainty lingers after an abandoned sale process and repeated leadership changes.
  • The EHR products are legacy Allscripts assets with slower innovation than newer rivals.

Integrations

Veradigm EHRPractice FusionPayerpath payer networkVeradigm Network partner ecosystem
Full Veradigm profile →

Compare against the rest of End-to-End RCM

Deciding between these two?

First Pass tracks End-to-End RCM every week: funding, launches, and what changed since this page was written.